Xyotax paclitaxel poliglumex: Phase III discontinued

CTIC stopped the Phase III PGT305 PIONEER trial of Xyotax after observing an "aberrantly" low rate of deaths in the paclitaxel control group. The company said it

Read the full 271 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE